Skip to main content

Table 1 Studies showing the incidence and characteristics of neutropenia following alemtuzumab - based therapy in MS patients

From: A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes

Study

Treatment

No of patients

Incidence of neutropenia

Grade of neutropenia

Median time to neutropenia

Median duration of neutropenia

Treatment

Comments

Coles AJ et al., 2012 [16]

1rst year of infusion (24 mg/d)

1/161

0,60%

NA

NA

NA

NA

Febrile neutropenia

Willis et al, 2016 [9]

NA

1/100

1%

NA

Median time to development of acquired autoimmune manifestations was 995 days following first treatment.

NA

NA

None

Gaitán MI et al., 2017 [5]

1rst year of infusion (12 mg/d)

1

case report

IV

4 weeks

3 days

Granulocyte-stimulating factor (300 mg/day for 72 h)

Responsive to 1 cycle of G-SCF, but developed HSV-1 infection that needed advanced antibiotics

Gaitán MI et al., 2017 [5]

1rst year of infusion (12 mg/d)

1

case report

IV-III (two episodes)

6 and 8 weeks (two episodes)

3

Granulocyte-stimulating factor (300 mg/day for 72 h)

Responsive to 2 cycles of G-SCF. Febrile neutropenia andsinusitis that needed iv antibiotics

Baker D et al., 2017 [4]

1rst year of infusion (12 mg/d)

127/811

15,70%

I-II

NA

NA

 

Data from CARE-MS I and CARE-MS II.

Baker D et al., 2017 [4]

1rst year of infusion (12 mg/d)

5/811

0,60%

III-IV

NA

NA

2 patients developed agranulocytosis,the first teated with PLEX and the other with lenograstim

Data from CARE-MS I and CARE-MS II.

Baker D et al., 2017 [4]

2nd year of infusion

104/808

12,90%

I-II

NA

NA

 

Data from CARE-MS I and CARE-MS II.

Baker D et al., 2017 [4]

2nd year of infusion

12/808

1,50%

III-IV

NA

NA

 

Data from CARE-MS I and CARE-MS II.

Vakrakou. et al., 2018 [17]

1rst year of infusion (12 mg/d)

1

case report

III

9 weeks

9 days

Prezolon (25 mg for 3 days and 12,5 mg for another 3 days)

LGL cells predominated in peripheral blood

Galgani S et al., 2018 [6]

1rst year of infusion (12 mg/d)

1

Case report

III/IV

1 month

2 weeks

Resolved spontaneously